Category: AnHeart

PharmaShots Weekly Snapshots (September 27 – October 01, 2021)

BMS Reports EMA’s Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma Published: Oct 1, 2021 | Tags: BMS, EMA, MAA, Relatlimab, Nivolumab, Metastatic Melanoma Merck and Ridgeback Report Interim Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 Published: Oct 1, 2021 | Tags: Merck, […]

Innovent and AnHeart Report Interim Results of Taletrectinib (AB-106) in P-II TRUST Trial for the Treatment of ROS1-Positive NSCLC at CSCO 2021

Shots: The P-II TRUST trial evaluates taletrectinib (AB-106, ROS1/NTRK inhibitor) in 37 TKI-naïve or pre-treated patients with ROS1-positive NSCLC As of June 16, 2021 cut off data, the therapy demonstrated an ORR (90.5% & 43.8%) & DCR (90.5% & 75.0%) in treatment-naïve & pre-treated patient. ROS1 G2032R resistant mutations were observed in three pre-treated patients […]